Acalabrutinib dihydrate is a selective Bruton’s tyrosine kinase (BTK) inhibitor used in cancer therapy. It is mainly indicated for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also used for mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is grouped under the following drug class(es): Antineoplastic agents and Kinase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include UNII-F86EN73XQR and RefChem:1075163. Its PubChem CID is 156749065.
Acalabrutinib dihydrate
| CAS No | 2648852-74-6 |
|---|---|
| Molecular Formula | C26H27N7O4 |
| Molecular Weight | 501.5 g/mol |
| Synonyms | 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide;dihydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Acalabrutinib dihydrate is a selective Bruton's tyrosine kinase (BTK) inhibitor used in cancer therapy. It is mainly indicated for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The listed CAS number is 2648852-74-6.
The listed molecular formula is C26H27N7O4.
The listed molecular weight is 501.5 g/mol.
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide;dihydrate.
The source lists UNII-F86EN73XQR and RefChem:1075163.